BMS-663068, a safe and effective HIV-1 attachment inhibitor

The Lancet HIV

Volume 2, Issue 10, October 2015, Pages e404-e405

TJ Henrich et al.
HIV-1 entry inhibitors: recent development and clinical use
Curr Opin Virol
(2013)
JA Este et al.
HIV entry inhibitors
Lancet
(2007)
B Nowicka-Sans et al.
In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068
Antimicrob Agents Chemother
(2012)
RE Nettles et al.
Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects
J Infect Dis
(2012)
JP Lalezari et al.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial
Lancet HIV
(2015)

There are more references available in the full text version of this article.